These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 488153)

  • 1. Changes of the immunogenic properties of K36 lymphoma treated in vivo with 5(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC).
    Bonmassar A; Frati L; Fioretti MC; Romani L; Giampietri A; Goldin A
    Eur J Cancer (1965); 1979 Jul; 15(7):933-9. PubMed ID: 488153
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of normal histocompatibility antigens in murine lymphomas treated with 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo.
    Taramelli D; Romani L; Bonmassar A; Goldin A; Fioretti MC
    Eur J Cancer (1965); 1981 Apr; 17(4):411-20. PubMed ID: 6171429
    [No Abstract]   [Full Text] [Related]  

  • 3. Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo.
    Riccardi C; Fioretti MC; Giampietri A; Puccetti P; Goldin A
    Transplantation; 1978 Feb; 25(2):63-8. PubMed ID: 146282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
    Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
    Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell kinetics and immunoegenicity of lymphoma cells treated with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC) in vivo.
    Silvestrini R; Testorelli C; Goldin A; Nicolin A
    Int J Cancer; 1977 May; 19(5):664-9. PubMed ID: 863544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound.
    Giampietri A; Fioretti MC; Goldin A; Bonmassar E
    J Natl Cancer Inst; 1980 Feb; 64(2):297-301. PubMed ID: 6928222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo.
    Santoni A; Kinney Y; Goldin A
    J Natl Cancer Inst; 1978 Jan; 60(1):109-12. PubMed ID: 146746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo.
    Romani L; Fioretti MC; Bonmassar E
    Transplantation; 1979 Sep; 28(3):218-22. PubMed ID: 494379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appearance of strong transplantation antigens in non-immunogenic lymphoma following drug-treatment in vivo.
    Fioretti MC; Romani L; Bonmassar A; Taramelli D
    J Immunopharmacol; 1980; 2(2):189-212. PubMed ID: 6821551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunochemotherapy of a transplantable AKR leukemia (K36).
    Putman DL; Kind PD; Goldin A; Kende M
    Int J Cancer; 1978 Feb; 21(2):230-3. PubMed ID: 24004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
    Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked histoincompatibility between and within sublines of AKR mice used in a syngeneic leukemia model.
    Graff RJ; Valeriote F; Medoff G
    J Natl Cancer Inst; 1975 Oct; 55(4):1015-6. PubMed ID: 1102719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of skin in Gross leukemia. 3. Quantitation of the role of tumor cells.
    Mariani T; Maruyama Y; Good RA
    J Natl Cancer Inst; 1972 Feb; 48(2):363-6. PubMed ID: 4568966
    [No Abstract]   [Full Text] [Related]  

  • 14. Radioresistant inhibition of lymphoma growth in congenitally athymic (nude) mice.
    Campanile F; Crino L; Bonmassar E; Houchens D; Goldin A
    Cancer Res; 1977 Feb; 37(2):394-8. PubMed ID: 832264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity.
    Fioretti MC; Bianchi R; Romani L; Bonmassar E
    J Natl Cancer Inst; 1983 Dec; 71(6):1247-51. PubMed ID: 6581361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of skin in gross leukemia. V. Refutation of virus involvement.
    Mariani T; Maruyama Y
    J Natl Cancer Inst; 1974 Dec; 53(6):1661-4. PubMed ID: 4612164
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
    Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
    Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effects of antineoplastic agents and anti-lymphoma allograft reactions.
    Riccardi C; Bartocci A; Puccetti P; Spreafico F; Bonmassar E; Goldin A
    Eur J Cancer (1965); 1980 Jan; 16(1):23-33. PubMed ID: 7358077
    [No Abstract]   [Full Text] [Related]  

  • 19. Prolonged survival of AKR mice following allogeneic bone marrow transplantation.
    Rose WC; Bortin MM; Saltzstein EC
    Experientia; 1974 Sep; 30(9):1085-6. PubMed ID: 4153447
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of pyran copolymer on leukemogenesis in immunosuppressed AKR mice.
    Hirsch MS; Black PH; Wood ML; Monaco AP
    J Immunol; 1973 Jul; 111(1):91-5. PubMed ID: 4351539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.